Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Kiara Gitta FarkasInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0009-0002-7533-5764
Katalin VinczeInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
Csongor TordaiInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0000-0001-9770-997X
Ece İlay ÖzgenDepartment of Molecular Biology and Genetics, Bilkent University, 06800 Ankara, Turkey.
Derin GürlerDepartment of Molecular Biology and Genetics, Bilkent University, 06800 Ankara, Turkey.
Vera DeliInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
Julianna LilienbergInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
Zsuzsa ErdeiInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0009-0003-0537-7421
Balázs SarkadiInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0000-0003-0592-4539
János Miklós RéthelyiDepartment of Psychiatry and Psychotherapy, Semmelweis University, H-1083 Budapest, Hungary.
Ágota ApátiInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0000-0003-0380-8139
Funding
National Research, Development and Innovation Office 2024-1.1.1-KKV_FÓKUSZ-2024-00022National Research, Development and Innovation Office GINOP-2.1.1-15-2015-00369National Research, Development and Innovation Office Hungarian Scientific Research Fund (OTKA) K-128369National Research, Development and Innovation Office National Brain Research Program (NAP) 2017-1.2.1-NKP-2017-00002National Research, Development and Innovation Office TKP2021-EGA-25
6 · The paper itself
Abstract
Schizophrenia is a complex psychiatric disorder of complex etiology. Despite decades of antipsychotic drug development and treatment, the mechanisms underlying cellular drug effects remain incompletely understood. Induced pluripotent stem cell (iPSC)-based disease and pharmacological modelling offer new avenues for drug development. In this study, we explored the development of two- and three-dimensional neural progenitor cultures and the impact of different antipsychotics in a schizophrenia model. Four human iPSC lines, including two carrying a de novo
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Functional Analysis of Antipsychotics in Human iPSC-Based Neural Progenitor 2D and 3D Schizophrenia Models. · full record | OpenQuestion